CHEK2 and cancer: This strongly supports the concept that cancer-directed therapies positively select for clones containing somatic variants in DDR genes, such as TP53, PPM1D, and CHEK2, but also that these clones have relatively lower fitness in the absence of exposure to cytotoxic therapy (Bolton et al., 2020).